Among the 21 patients with AML, 10 were classified as AML with recurrent genetic abnormalities (50) [biallelic mutation of CEBPA, n = 1; NPM1, n = 2; KMT2A rearrangement, n = 2; inv16 (p13.1q22), n = 2; t(8;21)(q22;q22.1), n = 1; RUNX1 mutation, n = 2], one patient had AML associated with Down syndrome, one patient had AML with myelodysplasia related changes, and the remaining nine patients had AML not otherwise specified. This evidence concerns the gene NPM1 and Myelodysplasia.